AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma
Glioblastoma (GB) is the most common primary brain tumor, which is characterized by low immunogenicity of tumor cells and prevalent immunosuppression in the tumor microenvironment (TME). Targeted local combination immunotherapy is a promising strategy to overcome these obstacles. Here, we evaluated...
Main Authors: | M.I. Strecker, K. Wlotzka, F. Strassheimer, B. Roller, G. Ludmirski, S. König, J. Röder, C. Opitz, T. Alekseeva, J. Reul, L. Sevenich, T. Tonn, W.S. Wels, J.P. Steinbach, C.J. Buchholz, M.C. Burger |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2127508 |
Similar Items
-
Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
by: Johanna Reul, et al.
Published: (2019-02-01) -
Comprehensive mutagenesis maps the effect of all single-codon mutations in the AAV2 rep gene on AAV production
by: Nina K Jain, et al.
Published: (2024-03-01) -
Evading the AAV Immune Response in Mucopolysaccharidoses
by: Matthew Piechnik, et al.
Published: (2020-05-01) -
Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
by: Mathieu Mével, et al.
Published: (2024-03-01) -
Evaluation of AAV-DJ vector for retinal gene therapy
by: Yusaku Katada, et al.
Published: (2019-01-01)